28 reports of this reaction
2.3% of all DEXTROMETHORPHAN POLISTIREX reports
#7 most reported adverse reaction
SOMNOLENCE is the #7 most commonly reported adverse reaction for DEXTROMETHORPHAN POLISTIREX, manufactured by Haleon US Holdings LLC. There are 28 FDA adverse event reports linking DEXTROMETHORPHAN POLISTIREX to SOMNOLENCE. This represents approximately 2.3% of all 1,242 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN POLISTIREX who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for DEXTROMETHORPHAN POLISTIREX, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for DEXTROMETHORPHAN POLISTIREX:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 28 FDA reports for DEXTROMETHORPHAN POLISTIREX. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 2.3% of all adverse event reports for DEXTROMETHORPHAN POLISTIREX, making it a notable side effect.
If you experience somnolence while taking DEXTROMETHORPHAN POLISTIREX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.